Drug Approval | March 04, 2023
Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
Jan Aushadhi highlights achievements of women of the country at 34 locations by felicitating all women stakeholders under the scheme
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
he product will be launched shortly in the US market.
With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).
This order is subject to initial advance payment as per the agreed terms of the contract
This combination medicine is used to treat high blood pressure (hypertension).
Subscribe To Our Newsletter & Stay Updated
